Krystal Biotech Q3 net income triples

Krystal Biotech

03/11/2025 12:09

Overview

Krystal Biotech Q3 2025 product revenue rises to $97.8 mln, up from $83.8 mln in 2024

Net income for Q3 2025 increases to $79.4 mln from $27.2 mln in 2024

Company launched VYJUVEK in Germany in Q3, France and Japan in Q4

Outlook

Company expects cystic fibrosis interim data readout in Q4 2025

Krystal Biotech anticipates pricing negotiations in Germany to continue until at least 2H 2026

Company projects non-GAAP R&D and SG&A expenses between $145 mln and $155 mln for FY 2025

Result Drivers

VYJUVEK LAUNCHES - Launched in Germany, contributing to revenue growth

EXPANDED LABEL - FDA approval expanded VYJUVEK's eligible patient population in the U.S.

HIGH GROSS MARGIN - Achieved a gross margin of 96% for the quarter

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Product Revenue
$97.80 mln
Q3 Net Income
$79.36 mln
Q3 Operating Expenses
$56.42 mln
Q3 Operating Income
$41.37 mln


Press Release: ID:nGNXbjL9C3

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)